New drug may slash heart risks after attack, study finds
NCT ID NCT04951856
First seen Jan 09, 2026 · Last updated May 09, 2026 · Updated 15 times
Summary
This study tests whether a powerful cholesterol-lowering drug called evolocumab can help people who have had a heart attack. About 2,166 participants will receive either evolocumab or standard care. The goal is to see if the drug lowers LDL cholesterol more effectively and reduces the risk of death or unplanned hospital visits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSTEMI - NON-ST SEGMENT ELEVATION MI are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ACTION Group, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière (APHP), UPMC
Paris, 75013, France
Conditions
Explore the condition pages connected to this study.